Lipocine Announces Realignment And Forward Focus On Treating CNS Disorders; Announces Planned Monetization Of Non-Core Assets Through Partnerships
Company to apply its proprietary Lip'ral oral drug delivery technology to advance a pipeline of differentiated products for Central Nervous System (CNS) disorders
Initial focus on oral delivery of neuroactive